Showing results (181-190 of 211) with videos related to
Sort By:
Pageof 22
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2000
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicityD B Axworthy, J M Reno, M D Hylarides, et al.Blood|June 19, 2002
Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213Meili Zhang, Zhengsheng Yao, Kayhan Garmestani, et al.Chest|September 1, 1984
Physiologic aspects of human heart-lung transplantation. Pulmonary function status of the post-transplanted lungJ Theodore, S W Jamieson, C M Burke, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 7, 2003
Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenograftsKrishnan Subbiah, Don K Hamlin, John M Pagel, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 12, 2004
Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2Nai-Kong V Cheung, Shakeel Modak, Yukang Lin, et al.The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 1, 1994
Long-term results of combined heart-lung transplantation: the Stanford experienceG E Sarris, J A Smith, N E Shumway, et al.Journal of Neurology|October 20, 2011
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MSBianca Weinstock-Guttman, Steven L Galetta, Gavin Giovannoni, et al.The New England Journal of Medicine|September 21, 2012
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisRobert J Fox, David H Miller, J Theodore Phillips, et al.The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 1, 1996
Risk factors for the development of obliterative bronchiolitis after lung transplantationR E Girgis, I Tu, G J Berry, et al.The Lancet. Neurology|February 10, 2009
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyEva Havrdova, Steven Galetta, Michael Hutchinson, et al.Pageof 22